|Exhaled nitric oxide is decreased by exposure to the hyperbaric oxygen therapy environment.|
|Jump to Full Text|
|PMID: 17392577 Owner: NLM Status: MEDLINE|
|METHODS: Part 1, eNO was measured before and after HBOT. Part 2, normal subjects breathed 40% oxygen.
RESULTS: Baseline eNO levels in patients prior to HBOT exposure were significantly higher than in normal subjects (P < .05). After HBOT, eNO significantly decreased in patients (15.4 +/- 2.0 versus 4.4 +/- 0.5 ppb, P < .001), but not in normal subjects, after either 100% O2 at increased pressure or 40% oxygen, 1 ATA. In an in vitro study, nitrate/nitrite release decreased after 90 minutes HBOT in airway epithelial (A549) cells.
CONCLUSION: HBO exposure causes a fall in eNO. Inducible nitric oxide synthase (iNOS) may cause elevated eNO in patients secondary to inflammation, and inhibition of iNOS may be the mechanism of the reduction of eNO seen with HBOT.
|Zudin A Puthucheary; Jia Liu; Michael Bennett; Barbara Trytko; Sharron Chow; Paul S Thomas|
Related Documents :
|8339807 - Effect of frusemide on cough responses to chloride-deficient solution in normal and mil...
20460257 - Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapn...
8520737 - Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals.
217557 - Toluene di-isocyanate-induced asthma. ii. inhalation challenge tests and bronchial reac...
3957827 - Oxygen delivery and utilization in hypothermic dogs.
8039437 - Changes in left ventricular ejection fraction during transient myocardial ischaemia in ...
|Type: Journal Article|
|Title: Mediators of inflammation Volume: 2006 ISSN: 0962-9351 ISO Abbreviation: Mediators Inflamm. Publication Date: 2006|
|Created Date: 2007-03-29 Completed Date: 2007-04-24 Revised Date: 2013-06-06|
Medline Journal Info:
|Nlm Unique ID: 9209001 Medline TA: Mediators Inflamm Country: United States|
|Languages: eng Pagination: 72620 Citation Subset: IM|
|UNSW and Department of Respiratory Medicine, Faculty of Medicine, Prince of Wales Hospital, Randwick, NSW, Australia.|
|APA/MLA Format Download EndNote Download BibTex|
Hyperbaric Oxygenation* / adverse effects
Inflammation Mediators / metabolism*
Lung / metabolism
Nitric Oxide / metabolism*
Nitric Oxide Synthase Type II / antagonists & inhibitors, metabolism
|0/Biological Markers; 0/Inflammation Mediators; 10102-43-9/Nitric Oxide; EC 22.214.171.124/Nitric Oxide Synthase Type II|
Journal ID (nlm-ta): Mediators Inflamm
Journal ID (publisher-id): MI
Publisher: Hindawi Publishing Corporation
Copyright ? 2006 Zudin A. Puthucheary et al.
open-access: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received Day: 30 Month: 5 Year: 2006
Revision Received Day: 24 Month: 8 Year: 2006
Accepted Day: 25 Month: 8 Year: 2006
Print publication date: Year: 2006
Electronic publication date: Day: 28 Month: 9 Year: 2006
Volume: 2006 Issue: 5
E-location ID: 72620
PubMed Id: 17392577
|Exhaled Nitric Oxide is Decreased by Exposure to the Hyperbaric Oxygen Therapy Environment|
|Zudin A. Puthucheary1|
|Paul S. Thomas1*|
1UNSW and Department of Respiratory Medicine, Faculty of Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia
2Hyperbaric Unit, Prince of Wales Hospital, Randwick, NSW 2031, Australia
|Correspondence: *Paul S. Thomas: email@example.com
Exhaled nitric oxide (eNO) is a marker of airway inflammation . Although NO is produced in the airways by a variety of cells, large amounts may be generated from those involved in the acute and chronic inflammatory responses . NO plays a role in pulmonary host defence mechanisms, and is thought to have both bactericidal and bacteriostatic effects [3, 4]. Exhaled NO is released by nitric oxide synthases (NOS), including neuronal NOS (nNOS, Type 1), inducible NOS (iNOS, Type 2), and endothelial NOS (ecNOS, Type 3). These NOS isoforms have been demonstrated in the airways of many mammalian species including man [5, 6]. iNOS is generally not expressed unless the cells have been induced by certain cytokines, however, when stimulated, high concentrations (?M) of NO are produced [7?9]. Thus, an increase in exhaled NO may be due to upregulation of iNOS within epithelial cells in response to proinflammatory cytokines and oxidants [10, 11].
In recent years, eNO has been used as a sensitive marker of asthmatic airway inflammation [12, 13]. The assay is easy to perform and reproducible with clinically useful sensitivity and specificity .
Hyperbaric oxygen therapy (HBOT) is used for the treatment of a number of conditions associated with tissue hypoxia, including late radiation tissue injury and diabetic foot ulcers. These conditions are associated with hypoxia at the site of disease, and improving oxygenation may assist in the resolution of these lesions. Despite these beneficial effects, HBOT is associated with some undesirable side effects. Hyperoxia has long been associated with tissue damage and the development of lung diseases. The mechanism is not fully understood, but may be attributed to reactive oxygen species (producing oxygen free radicals, ROS) which induce the pulmonary cytochrome P450 enzymes [14?16]. This is supported by animal research into neonatal bronchopulmonary dysplasia, which has shown an arrest in alveolar and capillary development in positive pressure ventilated animals . It has been reported that ventilation with atmospheric hyperoxia in isolated perfused lungs increased NO generation [18, 19]. Conflicting reports in the literature have been described in studies of humans breathing 100% O2 [20, 21]. These changes associated with hyperoxia have been explained by the bonding of oxygen free radicals (O?) to extracellular NO in the body generating peroxynitrite (ONOO?) which is a strong oxidant and which has been reported to increase iNOS expression [22?25]. However, not all studies are consistent with these findings and hyperbaric oxygenation (HBO) has been shown to decrease NO generation in animal models of shock, perhaps via a decrease in the activity of iNOS .
This study aimed to measure alterations in eNO following a standard hyperbaric oxygen regime in those with tissue hypoxia and to compare them with normal subjects who were either attendants in the HBO chamber or who breathed supplemental oxygen at sea level. It was hypothesised that hyperoxia could downregulate exhaled nitric oxide. In addition it was hypothesised that the changes in eNO would be reflected in the ability of isolated pulmonary cells to generate nitrite in vitro under similar conditions as experienced by the patients.
Following the ethics committee's approval of the experimental protocol and written informed consent, patients undergoing HBO at the Prince of Wales Hospital Department of Diving and Hyperbaric Medicine were recruited to the study. All patients were undergoing HBOT for medical indications and no patient was subjected to HBOT purely for the sake of the study. These subjects were asked to complete a questionnaire detailing their medical history, current medications (particularly the use of glucocorticosteroids or nonsteroidal anti-inflammatory agents (NSAIDS)), and specific questions regarding the diagnoses of asthma, chronic obstructive pulmonary disease or other pulmonary diseases, diabetes mellitus, and ischemic heart disease. Smoking history was obtained. Normal subjects were recruited from hospital staff and also completed the same questionnaire.
The sampling and measurement procedure was as follows: subjects were asked to inhale orally and exhale into a 2-liter gas impermeable bag with a one way valve, generating a positive pressure to close the velum [27, 28]. If unable to fill this in one breath, a second breath was used. The samples were then analysed within 60 minutes using a closed gas circuit connected to a chemiluminescent nitric oxide analyser, (Dasibi Environmental Corp, Glendale, Calif, USA) for NO and Spacelabs Capnograph Model 90513-30 (Redmond, Wash, USA) for CO2. The values obtained are therefore an average of mixed expired gas concentrations of one or two expirations.
All patients and attendants provided an expired NO sample prior to compression, the patients then underwent a standard 90-minute HBOT session at 2.4 atmospheres absolute (ATA), breathing 100% O2. These sessions involve a five to ten minute compression phase breathing air, 90 minutes breathing 100% oxygen at 2.4 ATA by demand valve mask or hood, and a further 20 minutes slow decompression while continuing to breathe oxygen. The total time in the chamber for each session is therefore approximately two hours. During this period they were accompanied by a trained hyperbaric chamber nursing attendant who breathed air during the compression and 2.4 ATA periods, before starting 100% oxygen for the 20-minute decompression phase. This is a standard operating procedure to reduce the risk of decompression illness for the attendant. For our experimental protocol, the attendants supplied a further sample of expired gas at 2.4 ATA before starting their oxygen breathing period.
Immediately on exiting the hyperbaric chamber, a further exhaled NO sample was taken from patients and staff.
A separate section studied normal subjects breathing 40% oxygen for 90 minutes via a face mask at 1 ATA. Exhaled NO samples were collected every 15 minutes.
A549 cells, an immortalised cell line derived from a lung epithelial cell carcinoma, were used as a model of airway epithelium. These cells have been demonstrated to be able to express iNOS and to be able to generate nitrite . Four plates of 2 ? 4 ? 106 A549 cells were incubated in F12-K media with 10% foetal calf serum (FCS) and exposed to the following conditions for 90 min: (a) room temperature and ambient air (plate A); (b) 100% oxygen at normal pressure (plate B); (c) air at 2.4 ATA pressure (plate C); and (d) 100% oxygen at 2.4 ATA (plate D). Interferon gamma is known to stimulate A549 cells to increase NO production . Under each of the conditions, A549 cells were therefore cultured in media with 0, 10, and 20 ng/mL recombinant human interferon gamma (hIFN ?, Serotec Ltd, UK). Nitrite/nitrate (NOx) was measured by using a fluorescent method . Samples were mixed with NADPH, FAD (Sigma, Sydney, Australia), and nitrate reductase with a final concentration of 50 ?M, 5 ?M, and 50 IU/L, respectively, and incubated in 37?C for 1 h, which allows nitrate to be converted to nitrite. Nitrite was conjugated with 0.05 mg/mL 2,3-diaminonaphthalene (DAN) in 0.62 M HCL to allow quantification by fluorescence. The reaction was terminated with 2.8 M NaOH. The resultant fluorescence was immediately read on a CytoFluro Series 4000, Multiwell Plate Reader (Perseptive Biosystems, Mass, USA) at excitation 360/40, emission 395/25, gain 50, limit of detection 2 ?mol/L, mean (SD) intra-assay coefficient of variation 3.11(3.42)%. Data are expressed as % change from baseline.
Data are presented as mean ? SE. The results were analysed using changes in NO (ppb) and CO2 (mmHg), after the NO values were log transformed to the normal distribution . Student's t test was used to calculate P-values, which were considered significant if P < .05.
In total, 16 attendants and 15 patients were recruited. Of the patients, 12 were not on current glucocorticosteroid therapy and 10 were not current steroid or NSAID users (Table 1). One attendant omitted to collect a breath sample in the chamber and other two samples collected in the chamber were lost due to overexpansion and ultimate failure of the gas collection bag during decompression. Mean (SD) coefficient of variation of interbag exhaled NO levels was 6.36(1.17)%.
The initial mean eNO level in patients was significantly higher than both that in attendants (15.4 ? 2.0 ppb vs 7.6 ? 1.1 ppb, P < .05) and the normal subjects in Part 2 (5.3 ? 1.0 ppb, P < .01). No difference in the initial exhaled NO level was found between the attendants and normal subjects at 1 ATA (7.6 ? 1.1 ppb vs 5.3 ? 1.0 ppb, resp, P = .14).
eNO significantly decreased after HBOT (Figure 1, 15.4 ? 2.0 vs 4.4 ? 0.5 ppb, P < .001, n = 15). This effect was present in both the subgroup not on glucocorticosteroids (15.2 ? 2.3 vs 4.3 ? 0.6 ppb, P < .001, n = 12) and in the subgroup on neither glucocorticosteroids nor NSAIDs (16.1 ? 2.5 vs 4.4 ? 0.6 ppb, P < .001, n = 10). Exhaled CO2 showed a small but significant increase following HBOT in the patient group (25.5 mmHg ? 1.0 vs 27.3 mmHg ? 0.9, P < .05).
The mean exhaled NO level before hyperbaric exposure was 7.6 ? 1.1 ppb and the mean level was 7.9 ? 0.9 ppb (Figure 2, P = .46, n = 16) afterwards.
Mean exhaled NO levels in this normal group of subjects were 5.3 ? 1.0 ppb before and 4.6 ? 1.1 after 90-minute 40% oxygen inhalation (P = .22, n = 8), with no significant change in exhaled NO levels at any of the 15-minute intervals.
There was a significant decrease in NOx release into the cell culture media after exposure to 100% oxygen for 90 minutes in the A549 cells incubated in media alone (32.49% change from baseline vs 9.38%, P < .01) and media with 20 ng/mL hIFN ? (33.58% vs 9.25%, P < .05). The hyperbaric environment alone did not cause significant changes (32.49% vs 22.80%, P = .32 in media only, and 33.58% vs 20.64%, P = .29 in media with 20 ng/mL hIFN ?).
In this study, eNO levels of patients were significantly decreased after HBOT. In normal subjects eNO did not decrease significantly after either a short exposure to 100% oxygen during decompression, or 40% oxygen for 90 minutes in normal subjects. The decrease in eNO seen in the HBOT patient group has been observed in studies using oxygen at 1 ATA. For example, Tsuchiya demonstrated inhalation of 100% oxygen for 50 minutes reduced exhaled NO levels while inhalation of 40% oxygen in a second group of mechanically ventilated human subjects undergoing surgery did not . It is possible, however, that endogenous NO might be affected by anaesthetic agents, surgery, the increased airway pressure during mechanical ventilation, and these individuals may not show the same response as spontaneously breathing individuals. It is worth noting that both our study and that of Tsuchiya showed that 40% oxygen inhalation did not change eNO levels significantly . The 40% oxygen inhalation was chosen as it allowed a conventional mask to be used, but it would have been a more accurate comparison of the equivalent 2.4 ATA exposure if 50.4% oxygen had been used.
In Part 1 of this study, no significant changes in eNO levels were observed in normal subjects after breathing hyperbaric air at 2.4 ATA for 90 minutes. This exposure is equivalent to breathing 50.4% oxygen at 1 ATA (the inspired pO2 is approximately 361 mmHg in each case). Compared with the hyperbaric oxygen at the same pressure inhaled by the patients, it could be concluded that pressure is not the main factor altering the eNO levels in this study, although these normal subjects had a lower baseline eNO.
The increase in exhaled CO2 in the patients is presumably due to either stimulation of NADPH turnover through the pentose cycle or, more likely, suppression of their hypoxic ventilatory drive [32?34].
The attendants received less hyperbaric oxygen exposure than the patients and we acknowledge this may bias the result towards no change in these individuals. In addition, this group was younger and generally more physically fit. The lack of inflammatory diseases in both control groups probably accounts for the difference in baseline eNO between them and the patients. Half of the patients had osteoradionecrosis of the head and neck, initial mean exhaled NO 15.0 ? 2.88 ppb, which may be associated with inflammation of the upper airway. Those without osteoradionecrosis, however, had a similar baseline exhaled NO. The reason for this is unclear but may be related to inflammation associated with their underlying condition with foot ulcers being the most common indication for HBOT. These conditions were associated with an elevated eNO above our normal range . Although this was a prospective study, patients were recruited at various times during their HBOT, which may have influenced the baseline exhaled NO values. It was hypothesised that the elevated baseline exhaled NO in the patients was related to the induction of iNOS. Inducible NOS is generally not expressed unless the cells have been activated by inflammatory cytokines [7?9, 36, 37].
Inhibition of iNOS in patients by HBOT may account for the decrease of eNO levels. Recent studies have demonstrated that oxidative stress also prevented iNOS induction in intestinal epithelial cells [38, 39]. Yuan et al showed that hyperbaric oxygen (HBO) suppressed iNOS expression in rabbit chondrocytes, and Pedoto et al reported that HBO decreased exhaled NO generation, plasma nitrite/nitrate concentration, and iNOS expression in the rat lung [26, 38, 40]. Absent or low levels of iNOS in normal subjects could explain why eNO levels did not change after oxygen inhalation.
Changes in production of ROS or inhibition of iNOS expression would be two possible reasons for the decrease in eNO after inhalation of high concentrations of oxygen for a long period although no study has addressed the effect of short exposure to HBOT in terms of oxidative status . ROS generally increase inflammation, which would be expected to increase iNOS expression. It is possible, however, that ROS could react with NO, and convert it to other NOx species. This seems unlikely as the in vitro studies showed a decline in NOx with O2 exposure.
It has been reported that a combination of interferon gamma and interleukin 4 stimulates and maintains iNOS expression in human airway epithelium . This study showed that NOx released from the A549 cell line incubated in media alone or with 20 ng/mL human interferon gamma significantly decreased after exposure to 100% oxygen, which occurred in the absence of HBO. This suggests that inhibition of iNOS may be the mechanism of the reduction in eNO seen in patients. It has been demonstrated that iNOS is expressed under resting conditions in the A549 cell line, which could explain the decrease in NOx release after 100% oxygen exposure in the A549 cell line incubated in media only .
In conclusion, our results suggest that inhibition of iNOS may be the mechanism of HBOT-induced reduction in eNO. This might have beneficial effects on inflammation, a question which could to be further investigated by measurement of iNOS expression in a randomized controlled study in response to hyperoxia.
The participation of patients and Hyperbaric Medicine Unit staff in the research is gratefully acknowledged.
|1.||Kharitonov SA,Gonio F,Kelly C,Meah S,Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and childrenEuropean Respiratory Journal 2003;21(3):433–438. [pmid: 12661997]|
|2.||Yates DH. Role of exhaled nitric oxide in asthmaImmunology and Cell Biology 2001;79(2):178–190. [pmid: 11264714]|
|3.||Dukelow AM,Weicker S,Karachi TA,et al. Effects of nebulized diethylenetetraamine-NONOate in a mouse model of acute pseudomonas aeruginosa pneumoniaChest 2002;122(6):2127–2136. [pmid: 12475857]|
|4.||Hucke C,MacKenzie CR,Adjogble KDZ,Takikawa O,D?ubener W. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenaseInfection and Immunity 2004;72(5):2723–2730. [pmid: 15102781]|
|5.||Deynin A,Massaro AF,Kobzik L,De Sanctis GT,Drazen JM. Marczin N,Kharitonov SA,Yacoub MH,Barnes PJMolecular and cellular sources of exhaled nitric oxideDisease Markers in Exhaled Breath 2003New York, NY: Marcel Dekker; :73–89. Chapter 3.|
|6.||Asano K,Chee CBE,Gaston B,et al. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cellsProceedings of the National Academy of Sciences of the United States of America 1994;91(21):10089–10093. [pmid: 7524082]|
|7.||Andrew PJ,Mayer B. Enzymatic function of nitric oxide synthasesCardiovascular Research 1999;43(3):521–531. [pmid: 10690324]|
|8.||Hecker M,Cattaruzza M,Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cellsGeneral Pharmacology 1999;32(1):9–16. [pmid: 9888247]|
|9.||Albrecht EWJA,Stegeman CA,Heeringa P,Henning RH,van Goor H. Protective role of endothelial nitric oxide synthaseJournal of Pathology 2003;199(1):8–17. [pmid: 12474221]|
|10.||Dupuy PM,Frostell CG. Zapol WM,Bloch KDBronchial effects of nitric oxideNitric Oxide and the Lung 1997New York, NY: Mercel Dekker; :285–312. Chapter 15.|
|11.||Karupiah G,Xie Q-W,Buller RML,Nathan C,Duarte C,MacMicking JD. Inhibition of viral replication by interferon-?-induced nitric oxide synthaseScience 1993;261(5127):1445–1448. [pmid: 7690156]|
|12.||Kharitonov SA,Yates D,Robbins RA,Logan-Sinclair R,Shinebourne EA,Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patientsLancet 1994;343(8890):133–135. [pmid: 7904001]|
|13.||Yates DH,Kharitonov SA,Robbins RA,Thomas PS,Barnes PJ. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxideAmerican Journal of Respiratory and Critical Care Medicine 1995;152(3):892–896. [pmid: 7663801]|
|14.||Gerschman R,Gilbert DL,Nye SW,Dwyer P,Fenn WO. Oxygen poisoning and x-irradiation: a mechanism in commonScience 1954;119(3097):623–626. [pmid: 13156638]|
|15.||Jamieson D,Chance B,Cadenas E,Boveris A. The relation of free radical production to hyperoxiaAnnual Review of Physiology 1986;48:703–719.|
|16.||Couroucli XI,Welty SE,Geske RS,Moorthy B. Regulation of pulmonary and hepatic cytochrome P4501A expression in the rat by hyperoxia: implications for hyperoxic lung injuryMolecular Pharmacology 2002;61(3):507–515. [pmid: 11854430]|
|17.||Thomson MA,Yoder BA,Winter VT,et al. Treatment of immature baboons for 28 days with early nasal continuous positive airway pressureAmerican Journal of Respiratory and Critical Care Medicine 2004;169(9):1054–1062. [pmid: 14962819]|
|18.||Nozik ES,Huang Y-CT,Piantadosi CA. L-Arginine enhances injury in the isolated rabbit lung during hyperoxiaRespiration Physiology 1995;100(1):63–74. [pmid: 7541544]|
|19.||Suzuki K,Naoki K,Kudo H,et al. Impaired hypoxic vasoconstriction in intraacinar microvasculature in hyperoxia-exposed rat lungsAmerican Journal of Respiratory and Critical Care Medicine 1998;158(2):602–609. [pmid: 9700141]|
|20.||Schmetterer L,Findl O,Strenn K,et al. Role of NO in the O2 and CO2 responsiveness of cerebral and ocular circulation in humansAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology 1997;273(6):R2005–R2012.|
|21.||Tsuchiya M,Tokai H,Takehara Y,et al. Interrelation between oxygen tension and nitric oxide in the respiratory systemAmerican Journal of Respiratory and Critical Care Medicine 2000;162(4 pt 1):1257–1261. [pmid: 11029327]|
|22.||Cooke C-LM,Davidge ST. Peroxynitrite increases iNOS through NF-?B and decreases prostacyclin synthase in endothelial cellsAmerican Journal of Physiology - Cell Physiology 2002;282(2):C395–C402. [pmid: 11788351]|
|23.||Cucchiaro G,Tatum AH,Brown MC,Camporesi EM,Daucher JW,Hakim TS. Inducible nitric oxide synthase in the lung and exhaled nitric oxide after hyperoxiaAmerican Journal of Physiology - Lung Cellular and Molecular Physiology 1999;277(3):L636–L644.|
|24.||Beckman JS,Beckman TW,Chen J,Marshall PA,Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxideProceedings of the National Academy of Sciences of the United States of America 1990;87(4):1620–1624. [pmid: 2154753]|
|25.||Sato T,Takeda Y,Hagioka S,Zhang S,Hirakawa M. Changes in nitric oxide production and cerebral blood flow before development of hyperbaric oxygen-induced seizures in ratsBrain Research 2001;918(1-2):131–140. [pmid: 11684051]|
|26.||Pedoto A,Nandi J,Yang Z-J,et al. Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in ratsClinical and Experimental Pharmacology and Physiology 2003;30(7):482–488. [pmid: 12823263]|
|27.||Kharitonov S,Alving K,Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendationsThe European Respiratory Journal 1997;10(7):1683–1693. [pmid: 9230267]|
|28.||American Thoracic Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children?1999American Journal of Respiratory and Critical Care Medicine 1999;160(6):2104–2117. [pmid: 10588636]|
|29.||Wei XM,Kim HS,Kumar RK,et al. Effects of cigarette smoke on degranulation and NO production by mast cells and epithelial cellsRespiratory Research 2005;6(1):108. [pmid: 16168067]|
|30.||Robbins RA,Barnes PJ,Springall DR,et al. Expression of inducible nitric oxide in human lung epithelial cellsBiochemical and Biophysical Research Communications 1994;203(1):209–218. [pmid: 7521161]|
|31.||Misko TP,Schilling RJ,Salvemini D,Moore WM,Currie MG. A fluorometric assay for the measurement of nitrite in biological samplesAnalytical Biochemistry 1993;214(1):11–16. [pmid: 7504409]|
|32.||Bassett DJ,Fisher AB. Glucose metabolism in rat lung during exposure to hyperbaric O2Journal of Applied Physiology 1979;46(5):943–949. [pmid: 468612]|
|33.||Donina, ZhA;Ivanov, AS.;Troshikhin, GV.Compensatory reactions of the rabbit respiratory system to hypoxic stimulation in hyperbaric conditions [in Russian]Aviakosmicheskaia i Ekologicheskaia Meditsina 1996;30(4):34–38. [pmid: 8991572]|
|34.||Fontanari P,Badier M,Guillot Ch,et al. Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa hydra 10 record human diveEuropean Journal of Applied Physiology 2000;81(4):325–328. [pmid: 10664092]|
|35.||Thomas PS,Gibson PG,Wang H,Shah S,Henry RL. The relationship of exhaled nitric oxide to airway inflammation and responsiveness in childrenJournal of Asthma 2005;42(4):291–295. [pmid: 16032938]|
|36.||Morris SM Jr,Billiar TR. New insights into the regulation of inducible nitric oxide synthesisAmerican Journal of Physiology 1994;266(6 pt 1):E829–E839. [pmid: 8023911]|
|37.||Meng Q-H,Springall DR,Bishop AE,et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosisJournal of Pathology 1998;184(3):323–331. [pmid: 9614386]|
|38.||Yuan L-J,Ueng SWN,Lin S-S,Yeh W-L,Yang C-Y,Lin PY. Attenuation of apoptosis and enhancement of proteoglycan synthesis in rabbit cartilage defects by hyperbaric oxygen treatment are related to the suppression of nitric oxide productionJournal of Orthopaedic Research 2004;22(5):1126–1134. [pmid: 15304289]|
|39.||Dijkstra G,Blokzijl H,Bok L,et al. Opposite effect of oxidative stress on inducible nitric oxide synthase and haem oxygenase-1 expression in intestinal inflammation: anti-inflammatory effect of carbon monoxideJournal of Pathology 2004;204(3):296–303. [pmid: 15476266]|
|40.||Luongo C,Imperatore F,Cuzzocrea S,et al. Effects of hyperbaric oxygen exposure on a zymosan-induced shock modelCritical Care Medicine 1998;26(12):1972–1976. [pmid: 9875906]|
|41.||Gerschman R,Gilbert D,Nye SW,Dwyer P,Fenn WO. Oxygen poisoning and X-irradiation: a mechanism in common. 1954Nutrition 2001;17(2):162. [pmid: 11683139]|
|42.||Guo FH,Uetani K,Haque SJ,et al. Interferon ? and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediatorsJournal of Clinical Investigation 1997;100(4):829–838. [pmid: 9259582]|
|Lumbar cord oedema||1||0|
Previous Document: Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique an...
Next Document: LIF upregulates expression of NK-1R in NHBE cells.